WFRF:(You Dongfang)
Sökning: WFRF:(You Dongfang) > A trans-omics asses...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 06616naa a2200565 4500 | |
| 001 | oai:lup.lub.lu.se:cc43223f-c21f-48c0-99d6-2a06a5be2c76 | |
| 003 | SwePub | |
| 008 | 230127s2023 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://lup.lub.lu.se/record/cc43223f-c21f-48c0-99d6-2a06a5be2c762 URI |
| 024 | 7 | a https://doi.org/10.1002/1878-0261.133452 DOI |
| 040 | a (SwePub)lu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a art2 swepub-publicationtype |
| 072 | 7 | a ref2 swepub-contenttype |
| 100 | 1 | a Chen, Jiajinu Nanjing Medical University4 aut |
| 245 | 1 0 | a A trans-omics assessment of gene–gene interaction in early-stage NSCLC |
| 264 | c 2022-12-05 | |
| 264 | 1 | b Wiley,c 2023 |
| 300 | a 15 s. | |
| 520 | a Epigenome-wide gene–gene (G × G) interactions associated with non-small-cell lung cancer (NSCLC) survival may provide insights into molecular mechanisms and therapeutic targets. Hence, we proposed a three-step analytic strategy to identify significant and robust G × G interactions that are relevant to NSCLC survival. In the first step, among 49 billion pairs of DNA methylation probes, we identified 175 775 G × G interactions with PBonferroni ≤ 0.05 in the discovery phase of epigenomic analysis; among them, 15 534 were confirmed with P ≤ 0.05 in the validation phase. In the second step, we further performed a functional validation for these G × G interactions at the gene expression level by way of a two-phase (discovery and validation) transcriptomic analysis, and confirmed 25 significant G × G interactions enriched in the 6p21.33 and 6p22.1 regions. In the third step, we identified two G × G interactions using the trans-omics analysis, which had significant (P ≤ 0.05) epigenetic cis-regulation of transcription and robust G × G interactions at both the epigenetic and transcriptional levels. These interactions were cg14391855 × cg23937960 (βinteraction = 0.018, P = 1.87 × 10−12), which mapped to RELA × HLA-G (βinteraction = 0.218, P = 8.82 × 10−11) and cg08872738 × cg27077312 (βinteraction = −0.010, P = 1.16 × 10−11), which mapped to TUBA1B × TOMM40 (βinteraction =−0.250, P = 3.83 × 10−10). A trans-omics mediation analysis revealed that 20.3% of epigenetic effects on NSCLC survival were significantly (P = 0.034) mediated through transcriptional expression. These statistically significant trans-omics G × G interactions can also discriminate patients with high risk of mortality. In summary, we identified two G × G interactions at both the epigenetic and transcriptional levels, and our findings may provide potential clues for precision treatment of NSCLC. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a G × G interactions | |
| 653 | a NSCLC | |
| 653 | a overall survival | |
| 653 | a prognosis | |
| 653 | a trans-omics | |
| 700 | 1 | a Song, Yunjieu Nanjing Medical University4 aut |
| 700 | 1 | a Li, Yiu University of Michigan4 aut |
| 700 | 1 | a Wei, Yongyueu Harvard University,Nanjing Medical University4 aut |
| 700 | 1 | a Shen, Sipengu Nanjing Medical University4 aut |
| 700 | 1 | a Zhao, Yangu Nanjing Medical University4 aut |
| 700 | 1 | a You, Dongfangu Nanjing Medical University4 aut |
| 700 | 1 | a Su, Liu Massachusetts General Hospital,Harvard University4 aut |
| 700 | 1 | a Bjaanæs, Maria Moksnesu Oslo university hospital4 aut |
| 700 | 1 | a Karlsson, Annau Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/lungcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Research Group Lung Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/lungcancer,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)med-akn |
| 700 | 1 | a Planck, Mariau Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/lungcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Research Group Lung Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/lungcancer,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-mpl |
| 700 | 1 | a Staaf, Johanu Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/lungcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Research Group Lung Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/lungcancer,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-jst |
| 700 | 1 | a Helland, Åslaugu Oslo university hospital,University of Oslo4 aut |
| 700 | 1 | a Esteller, Manelu Josep Carreras Leukaemia Research Institute (IJC),Catalan Institution for Research and Advanced Studies,University of Barcelona4 aut |
| 700 | 1 | a Shen, Hongbingu Nanjing Medical University4 aut |
| 700 | 1 | a Christiani, David C.u Massachusetts General Hospital,Harvard University4 aut |
| 700 | 1 | a Zhang, Ruyangu Harvard University,Nanjing Medical University4 aut |
| 700 | 1 | a Chen, Fengu Nanjing Medical University4 aut |
| 710 | 2 | a Nanjing Medical Universityb University of Michigan4 org |
| 773 | 0 | t Molecular Oncologyd : Wileyg 17:1, s. 173-187q 17:1<173-187x 1574-7891x 1878-0261 |
| 856 | 4 | u http://dx.doi.org/10.1002/1878-0261.13345x freey FULLTEXT |
| 856 | 4 8 | u https://lup.lub.lu.se/record/cc43223f-c21f-48c0-99d6-2a06a5be2c76 |
| 856 | 4 8 | u https://doi.org/10.1002/1878-0261.13345 |
Hitta mer i SwePub
- Av författaren/redakt...
- Chen, Jiajin
- Song, Yunjie
- Li, Yi
- Wei, Yongyue
- Shen, Sipeng
- Zhao, Yang
- visa fler...
- You, Dongfang
- Su, Li
- Bjaanæs, Maria M ...
- Karlsson, Anna
- Planck, Maria
- Staaf, Johan
- Helland, Åslaug
- Esteller, Manel
- Shen, Hongbing
- Christiani, Davi ...
- Zhang, Ruyang
- Chen, Feng
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Molecular Oncolo ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
